Simple Summary Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in
non-small cell lung cancer patients. These treatments are more effective the higher the …

Lung cancer is the leading cause of cancer-specific death among Canadians, with non-
small-cell lung cancer (nsclc) being the most common histologic variant. Despite advances …

The Food and Drug Administration (FDA) approval of immune checkpoint inhibitors has
dramatically changed treatment paradigms for patients with advanced-stage or metastatic …

Aim The treatment of non-small-cell lung cancer has changed after the development of the
immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its …

Background Tumor programmed death ligand one (PD-L1) expression has been studied in
several trials in non-small-cell lung cancer. Methods We assessed the potential role of PD …

Over the last decade, the immune checkpoint blockade targeting the programmed death
protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free …

Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1)
have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 …

PURPOSE In many cancers, the expression of immunomodulatory ligands leads to
immunoevasion, as exemplified by the interaction of PD-L1 with PD-1 on tumor-infiltrating …

Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy,
and radiotherapy have been the standard treatment for lung cancer, and targeted molecular …

Lung cancer remains a leading cause of cancer‐related mortality worldwide with the poor
prognosis. Encouragingly, immune checkpoint blockade targeting programmed death‐1 (PD …